买丽克·伊明.醒脑静联合依达拉奉治疗高血压脑出血疗效及其可能的作用机制[J].内科急危重症杂志,2019,25(2):126-129
扫码阅读全文
|
| DOI：10.11768/nkjwzzzz20190211 |
| 中文关键词: 高血压脑出血 醒脑静 依达拉奉 一氧化氮 胰岛素样生长因子 1 巨噬细胞移动抑制因子 |
| 英文关键词: |
| 基金项目:国家973科技项目（No：2012CB722405） |
|
| 摘要点击次数: 1922 |
| 全文下载次数: 3034 |
| 中文摘要: |
| 目的：探讨醒脑静联合依达拉奉治疗高血压脑出血的疗效及其对患者一氧化氮（NO）、胰岛素样生长因子-1（IGF-1）、巨噬细胞移动抑制因子（MIF）水平的影响。方法：选择92例高血压脑出血患者，按随机数字表法分为对照组和实验组，每组46例。在稳定血压、控制脑水肿和调控体温等内科治疗的基础上，实验组给予依达拉奉联合醒脑静治疗，对照组给予依达拉奉治疗，2组均治疗14d。比较2组患者治疗前、后颅内血肿体积、美国国立卫生研究院卒中量表(NIHSS)评分以及血清NO、IGF-1和MIF水平的变化，治疗后90d随访，比较2组患者的生活质量（SS-QOL量表评分）、生活能力（Barthel指数）与预后(mRS评估)情况。结果：治疗7、14d后，实验组的血肿体积明显较对照组小（P<0.05）。治疗3、7、14d后，2组患者的NIHSS评分较治疗后当日显著降低（P<0.05），且实验组显著低于对照组（P<0.05）。治疗14d后，2组患者NO和IGF-1水平明显升高，MIF水平显著降低，实验组患者的改善程度明显大于对照组（P<0.05）。治疗后90d，实验组和对照组的预后良好率分别为80.43%和60.87%(P<0.05)，实验组患者生活能力和生活质量显著高于对照组（P<0.05）。结论：在高血压脑出血治疗中应用醒脑静联合依达拉奉能够促进血肿吸收，改善神经功能缺损，调节NO、IGF-1和MIF水平。 |
| 英文摘要: |
| Objective: To explore the curative effect of Xingnaojing combined with edaravone in the treatment of patients with hypertensive intracerebral hemorrhage and its effect on nitric oxide (NO), insulin-like growth factor-1 (IGF-1) and macrophage migration inhibitory factor (MIF) levels. Methods: Ninety-two patients with hypertensive intracerebral hemorrhage were divided into control group and experimental group by random number table (46 cases for each group). Edaravone, and edaravone combined with Xingnaojing treatments were respectively used on the basis of medical treatment such as stabilizing blood pressure, controlling cerebral edema and regulating body temperature, etc. The two groups were treated for 14 days. The hematoma volume, National Institute of Health stroke scale (NIHSS) score, serum NO, IGF-1 and MIF levels before and after treatment in two groups were compared. The patients were followed up from 90th day after treatment. Quality of life (SS-QOL scale score), ability to live (Barthel index) and prognosis (mRS assessment) were compared between the two groups. Results: The hematoma volume after treatment for 7 days and 14 days in the experimental group was significantly lower than that in the control group correspondingly (P<0.05). After treatment for 3, 7 and 14 days, the NIHSS score in the two groups was significantly lower than that before treatment (P<0.05), and that in the experimental group was significantly lower than that in the control group (P<0.05). After treatment for 14 days, the NO and IGF-1 levels increased significantly, and the MIF levels reduced significantly in the two groups, more significantly in the experimental group than in the control group (P<0.05). After treatment for 90 days, the prognosis good rate in the experimental group and control group was 80.43% and 60.87% respectively (P<0.05). The life ability and the life quality in the experimental group were significantly improved as compared with those in the control group (P<0.05). Conclusions: Xingnaojing combined with edaravone in the treatment of hypertensive intracerebral hemorrhage can promote the absorption of hematoma, improve nerve function defect, and regulate NO, IGF-1 and MIF levels. |
|
|
|
|
